
CLVLY
Healthcare · Biotechnology · $362.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 17, 2025 | After the close | — | 0.44 | — |
| Feb 26, 2025 | Time not confirmed | — | 0.28 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | 0.13 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | 0.14 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | 0.05 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | 0.05 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | 0.10 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | 0.09 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | 0.00 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | 0.00 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | 0.10 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | 0.10 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | 0.03 | — |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic…
| Sep 30, 2018 |
| Time not confirmed |
| 0.00 |
| 0.03 |
| — |
| Jun 30, 2018 | Time not confirmed | 0.00 | 0.09 | — |
| Mar 31, 2018 | Time not confirmed | 0.00 | 0.09 | — |